664 related articles for article (PubMed ID: 9029114)
21. Cloning and expression of the complement receptor glycoprotein C from Herpesvirus simiae (herpes B virus): protection from complement-mediated cell lysis.
Huemer HP; Wechselberger C; Bennett AM; Falke D; Harrington L
J Gen Virol; 2003 May; 84(Pt 5):1091-1100. PubMed ID: 12692273
[TBL] [Abstract][Full Text] [Related]
22. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
23. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
Low PJ; Ai R; Ogata RT
J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC(nectin-1) with different affinities.
Connolly SA; Whitbeck JJ; Rux AH; Krummenacher C; van Drunen Littel-van den Hurk S; Cohen GH; Eisenberg RJ
Virology; 2001 Feb; 280(1):7-18. PubMed ID: 11162814
[TBL] [Abstract][Full Text] [Related]
26. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
27. Alternative pathway complement activation in rheumatoid arthritis.
El-Ghobarey A; Whaley K
J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
[TBL] [Abstract][Full Text] [Related]
28. Effect of gangliosides on activation of the alternative pathway of human complement.
Michalek MT; Bremer EG; Mold C
J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
[TBL] [Abstract][Full Text] [Related]
29. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
30. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
Ekdahl KN; Nilsson B
J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
[TBL] [Abstract][Full Text] [Related]
31. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
Vogt W; Schmidt G; Hinsch B
Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
[TBL] [Abstract][Full Text] [Related]
32. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
33. Active sites in complement component C3 mapped by mutations at indels.
Ogata RT; Ai R; Low PJ
J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
[TBL] [Abstract][Full Text] [Related]
34. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
DiScipio RG
Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
[TBL] [Abstract][Full Text] [Related]
35. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
Melamed J; Medicus RG; Arnaout MA; Colten HR
J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
[TBL] [Abstract][Full Text] [Related]
36. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
37. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
39. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
40. [Selective binding in vitro of a modified form of the C3 component of complement to human erythrocytes].
Micouin C; Hudry-Clergeon E; Roussel B; Battail N; Tournoud A; Colomb MG
Ann Immunol (Paris); 1983; 134C(2):237-53. PubMed ID: 6223572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
